Drug Search Results
More Filters [+]

CV-MG01

Alternative Names: cv-mg01, cvmg01, cv mg01
Latest Update: 2019-09-25
Latest Update Note: News Article

Product Description

CuraVacsCV-MGis a potentialbreakthroughin MG treatmentsand a potential therapeutic revolution for all autoimmune diseases being the first to possibly bring along-lastingimprovement and a potential cure to patients.

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CuraVac
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CV-MG01

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Muscle Weakness|Myasthenia Gravis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Myasterix Efficacy Phase 2/3 Study

P3

Active, not recruiting

Muscle Weakness|Myasthenia Gravis

2019-08-03

Recent News Events